

---

**Norway-Oslo: Vaccines**  
**2023/S 129-412898**

**Contract notice**

**Supplies**

**Legal Basis:**

Directive 2014/24/EU

**Section I: Contracting authority**

**I.1) Name and addresses**

Official name: Folkehelseinstituttet  
National registration number: 983 744 516  
Postal address: Lovisenberggata 8  
Town: OSLO  
NUTS code: NO Norge  
Postal code: 0456  
Country: Norway  
Contact person: Ole Andreas Fuglesang  
E-mail:  
Telephone: +47 21076629

**Internet address(es):**

Main address:  
Address of the buyer profile:

**I.3) Communication**

The procurement documents are available for unrestricted and full direct access  
Additional information can be obtained from the abovementioned address  
Tenders or requests to participate must be submitted electronically via:  
Tenders or requests to participate must be submitted to the abovementioned address

**I.4) Type of the contracting authority**

Ministry or any other national or federal authority, including their regional or local subdivisions

**I.5) Main activity**

Health

**Section II: Object**

**II.1) Scope of the procurement**

**II.1.1) Title:**

Hexavalent vaccine - a combination vaccine against diphtheria, tetanus, whooping cough, polio, Hib and hepatitis B  
Reference number: 23/01723

**II.1.2) Main CPV code**

33651600 Vaccines

---

**II.1.3) Type of contract**

Supplies

**II.1.4) Short description:**

The Norwegian Institute of Public Health would like to procure diphtheria, tetanus, whooping cough, polio, Haemophilus influenza type B, and hepatitis B combination vaccines (hexavalent vaccine) for babies in the Norwegian child vaccination programme. The procurement is carried out on behalf of the Ministry of Health and Care Services (HOD).

The contest is being held electronically in the CTM KGV and information given in the tender management tool, in the notice, and the tender documentation stipulates the rules and terms for the contest.

NIPH aims to award a contract to one tenderer for a contract period of 2+1+1 years, calculated from 01.01.2024, with the last two years being option years. NIPH would like the first delivery at the latest by the end of the 1st quarter of 2024.

**II.1.5) Estimated total value**

Value excluding VAT: 420 000 000.00 NOK

**II.1.6) Information about lots**

This contract is divided into lots: no

**II.2) Description****II.2.2) Additional CPV code(s)**

33651610 Diphtheria-pertussis-tetanus vaccines

33651620 Diphtheria-tetanus vaccines

33651670 Polio vaccines

33651680 Hepatitis B vaccines

**II.2.3) Place of performance**

NUTS code: NO Norge

**II.2.4) Description of the procurement:**

The Norwegian Institute of Public Health would like to procure diphtheria, tetanus, whooping cough, polio, Haemophilus influenza type B, and hepatitis B combination vaccines (hexavalent vaccine) for babies in the

Norwegian child vaccination programme. The procurement is carried out on behalf of the Ministry of Health and Care Services (HOD).

The contest is being held electronically in the CTM KGV and information given in the tender management tool, in the notice, and the tender documentation stipulates the rules and terms for the contest.

NIPH aims to award a contract to one tenderer for a contract period of 2+1+1 years, calculated from 01.01.2024, with the last two years being option years. NIPH would like the first delivery at the latest by the end of the 1st quarter of 2024.

The procurement consists of delivery of a hexavalent vaccine (ATC code: J07C A09) for vaccinating babies in the Norwegian child vaccination programme.

The following estimates for the annual number of doses that NIPH needs is based on a year made up of approx. 60,000 persons, and 3 doses are to be given to each person in order to achieve sufficient protection from the diseases.

The estimated annual vaccine requirement will be approx. 180,000 doses (per calendar year).

The estimated maximum scope for the contract period, with the full extension of the contract period (option), is estimated to be approx. 720,000 doses.

The Norwegian Institute of Public Health draws attention to the fact that this is only an estimate and the contracting authority is not bound by the estimated volume.

The Norwegian Institute of Public Health will, in accordance with the contract, procure a minimum volume 160,000 doses per calendar year in the contract period. (Supply agreement point 3.2).

Beyond the minimum volume, the volume that the Norwegian Public Health Authority will eventually order, will depend on demand.

The Norwegian Public Health Institute is not obligated to submit orders beyond the minimum requirement.

#### II.2.5) **Award criteria**

Criteria below

Quality criterion - Name: quality / Weighting: 30

Price - Weighting: 70

#### II.2.6) **Estimated value**

Value excluding VAT: 420 000 000.00 NOK

#### II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 24

This contract is subject to renewal: yes

Description of renewals:

The contract period is 2 years, with an option for 1+1 year extension. The option for an extension will be automatically taken up for one year at a time, unless the contracting authority gives notice on the contract in accordance with the Supply Agreement, point 17. The contracting authority aims to sign the contract shortly after the procurement is implemented.

#### II.2.10) **Information about variants**

Variants will be accepted: no

#### II.2.11) **Information about options**

Options: yes

Description of options:

The contract period is 2 years, with an option for 1+1 year extension. The option for an extension will be automatically taken up for one year at a time, unless the contracting authority gives notice on the contract in accordance with the Supply Agreement, point 17. The contracting authority aims to sign the contract shortly after the procurement is implemented.

---

**II.2.13) Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

**II.2.14) Additional information**

The procurement's total value, as stated in the notice point II.2.6) Estimated Value, is based on approved maximum prices (AIP).

**Section III: Legal, economic, financial and technical information****III.1) Conditions for participation****III.1.1) Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers**

List and brief description of conditions:

Tenderers must be registered in a company register, professional register or a trade register in the country where the tenderer is established.

Documentation requirement:

Norwegian companies: Company registration certificate

Foreign tenderers: Verification showing that the tenderer is registered in a company register, professional register or a commerce register in the country where the tenderer is established.

**III.1.2) Economic and financial standing**

List and brief description of selection criteria:

Tenderers must have sufficient economic and financial capacity to fulfil the contract. Creditworthiness with no requirement for guarantees will be sufficient to meet the requirement.

Documentation requirement:

Credit assessment based on the most recent accounting figures. The rating must be carried out by a credit rating agency with a licence to provide such service.

**III.1.3) Technical and professional ability**

List and brief description of selection criteria:

Tenderers must have the requisite permissions to be able to fulfil the contract.

Documentation requirement:

If the tenderer is the manufacturer of the vaccine, permission must be presented from relevant EU/EEA authorities to manufacture pharmaceuticals.

If the tenderer is not the manufacturer of the vaccine, the requisite permissions from relevant EU/EEA authorities to trade in pharmaceuticals must be presented.

If the tenderer imports the vaccine, the import license that includes the offered vaccine must be presented.

**III.2) Conditions related to the contract****III.2.2) Contract performance conditions:**

- The Norwegian Institute of Public Health requires ethical and socially responsible production. (Supply agreement point 12, 12.1 – 12.3).

- Tenderers must be a member of the Legemiddelansvarsforeningen [Pharmaceutical Liability Association] (Supply Agreement, point 11.2)

The Norwegian Institute of Public Health (NIPH) can re-sell, non-distributed, vaccine doses (Supply Agreement, point 18.1)

- NIPH is, for every year of the entire contract period, bound to procure a stated minimum number of doses (Supply Agreement point 3.2)

- The tenderer is, for every year of the entire contract period, obliged to deliver up to a stated maximum number of doses (Supply Agreement point 3.3)

- First delivery: The tenderer is obliged to deliver minimum 45,000 doses by 31.03.2024

---

**Section IV: Procedure****IV.1) Description****IV.1.1) Type of procedure**

Open procedure

**IV.1.3) Information about a framework agreement or a dynamic purchasing system****IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

**IV.2) Administrative information****IV.2.2) Time limit for receipt of tenders or requests to participate**

Date: 31/08/2023

Local time: 13:00

**IV.2.3) Estimated date of dispatch of invitations to tender or to participate to selected candidates****IV.2.4) Languages in which tenders or requests to participate may be submitted:**

English, Norwegian

**IV.2.6) Minimum time frame during which the tenderer must maintain the tender**

Tender must be valid until: 15/11/2023

**IV.2.7) Conditions for opening of tenders**

Date: 31/08/2023

Local time: 13:00

Place:

Tenders will be opened electronically in the contracting authority's KGV system.

Information about authorised persons and opening procedure:

Two employees with access to the KGV system must log in and each carry out their individual opening of the tenders.

**Section VI: Complementary information****VI.1) Information about recurrence**

This is a recurrent procurement: yes

**VI.2) Information about electronic workflows**

Electronic invoicing will be accepted

**VI.3) Additional information:**

Changes in responsibility for vaccine procurements from 01.01.2024

The revised national budget for 2023 included notified changes to health management, including a proposal to transfer responsibility for vaccine procurements from NIPH to the Norwegian Medicines Agency / Directorate for Medical Products (SLV/DMP) with effect from 01.01.2024.

Per June 2023, a project has been started to clarify how the responsibility is to be transferred. At the time of this notice, the transfer details have not been clarified. If changes are decided that are of importance for signed contracts, the contract can be transferred from NIPH to SLV/DMP or another public entity. NIPH will try to keep affected tenderers informed.

**VI.4) Procedures for review****VI.4.1) Review body**

---

Official name: Oslo tingrett  
Postal address: Postboks 2106 Vika  
Town: oslo  
Postal code: 0125  
Country: Norway  
Internet address:

VI.5) **Date of dispatch of this notice:**  
03/07/2023